🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

My friend and colleague Dr. Toon Van Gorp just presented the > 1000 pt study of adding pembro to T/C +/- radiation in the adjuvant therapy of endometrial cancer. Here are the take away points: 1. The primary endpoint of DFS was not met in the intention to treat arm. 2. Subset

The long awaited PRIMA OS presented today by Dr. Antonio Gonzalez-Martin! No difference in OS in all comers or in any subgroup. Importantly no deficit noted either. Use of subsequent therapy and subsequent PARPi was high and - along with long term post progression survival will

Improvements in platinum sensitive maintenance therapy continues to be elusive at ESMO - Eur. Oncology #ESMO2024 . EUDARIO added an HSP 90 inhibitor to niraparib and ICON 9 added cediranib to olaparib and both were negative. For the US at least- PARPi in 2nd line is no longer authorized

Exciting new options on the horizon for patients with recurrent ovarian, endometrial and cervical cancer : 3 Trop2 targeting ADCs were presented #ESMO2024 with relatively similar response rates (30-40%) and DOR > 6 months.

Results of phase I Rina-S, ADC targets FOLR. ORR 50% in the 120mg/m2 dose. Responses seen in both FOLR high and low tumors. SGO ESMO - Eur. Oncology #ESMO2024

Interesting talk by Jack Chan on interlace, induction chemo prior to chemort in LACC and the differences between Interlace and OUTBACK trials. SGO ESMO - Eur. Oncology

SGO's Capitol Hill Day - ✅ Special thanks to SGO members and patient advocacy org leaders for advocating today to advance gyn cancer care. Read through our asks and check out a few photos! Visit sgo.org/advocacy to read more about SGO's advocacy priorities and efforts.

Correlative Science in the Cooperative Group System—Re-Engineering for Success | Journal of Clinical Oncology ascopubs-org.webproxy2.ouhsc.edu/doi/full/10.12… "1. Correlative science is essential to advance the findings of major cooperative group clinical trials in the NCTN. 2. Patients contribute

What an inspiring 4 days at the 15th HHMT Intl Forum on Ovarian Cancer!Sharing our research and collaborating to overcome ovarian cancer Kunle Odunsi, MD Ernst Lengyel Ronny Drapkin 🎗 Dmitriy Zamarin MD PhD Anniina Färkkilä Stephanie Lheureux @rugangzhang @OCRAhope@OvarianCancerUK #forourpatients

Come to the Ovarian Cancer Midwest Focus meeting in November (18-19). Great line up of speakers and fun activities (as always)! ocmfconference.com Buckanovich Lab FarkkilaLab Analisa DiFeo Katherine Aird Ben Bitler Ernst Lengyel Katherine Fuh MD PhD Burdette Lab Ovarian Cancer Academy BasserBRCA

We are looking for a spatial experimental biologist! 🎯Please RT

In Nature Communications, we describe a comprehensive cell atlas of healthy human fallopian tubes during the menstrual cycle and menopause using single-cell RNA and ATAC sequencing. Melanie Weigert sarah olivia ackroyd UChicagoCancerCenter Mengjie Chen UChicago Obstetrics and Gynecology Department nature.com/articles/s4146…

#ASCO25 - abstract titles are here! Excited to see: 1. LBA5500 The long awaited TRUST trial 2. 5502: ctDNA analysis from CALLA! 3. PRO from OUTBACK 4. LBA 5505 FIRST 5. LBA 5507 ROSELLA 6. 5511 cis/pembro/rt in vulvar cancer 7. 5512 ctDNA from DUO E 8. 5515 Len/pem in clear cell

OCRA’s recent meeting featured members of our scientific leadership & included a recap of the latest clinical developments: bit.ly/3GAwBdC. #GynCSM

NIH guts its first and largest study centered on women | Science | AAAS science.org/content/articl… We must continue to speak up against the dismantling of our scientific programs. I am a scientist - I personally care for people with gynecologic cancer but I care about improving the

Registration & Housing for the WAGO 2025 Annual Meeting is Now Open! To register, click link in bio or go to ow.ly/Z7LR50VNSWA. To book hotel reservations, click link in bio or go to ow.ly/hXhV50VNSWz. #WAGO2025 #WAGO

At WAGO meeting- in 2025, only 3.4% of NCI funding goes to funding gyn cancer research, despite endometrial cancer and ovarian cancer being 2 of the top 10 causes of cancer deaths. Endometrial cancer incidence and mortality is also increasing. We must change this.

Congratulations to our trainees on their fantastic presentations at #WAGO2025!! Western Association of Gynecologic Oncologists UCSF Obstetrics Gynecology & Reproductive Sciences

Proud to share our new nature study: We developed the 1st NNMT inhibitor that reprograms cancer-associated fibroblasts, boosting immune response & stopping tumor growth in ovarian cancer models, especially when paired with immunotherapy. Lengyel Lab nature.com/articles/s4158…

I cannot stress this enough: pairing a 4% funding line with the largest cut in NCI history will devastate the future of cancer research - and patients. We would be turning our backs on decades of progress.